| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5552394 | APIL | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(9 years ago) | |
| US6652880 | APIL | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
Mar, 2020
(4 years ago) | |
Taytulla is owned by Apil.
Taytulla contains Ethinyl Estradiol; Norethindrone Acetate.
Taytulla has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Taytulla are:
- US5552394
- US6652880
Taytulla was authorised for market use on 19 April, 2013.
Taytulla is available in capsule;oral dosage forms.
Taytulla can be used as prevention of pregnancy.
The generics of Taytulla are possible to be released after 29 March, 2020.
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 19 April, 2013
Treatment: Prevention of pregnancy
Dosage: CAPSULE;ORAL
More Information on Dosage
TAYTULLA family patents
